Cordis SELUTION SLR SUSTANE drug-eluting balloon shows highest 12-month primary patency in US IDE trial

The Cordis SELUTION SLR SUSTANE PTA Drug-Eluting Balloon (SUSTANE DEB) achieved the highest reported 12-month primary patency in the SELUTION4SFA US pivotal trial at 90.3%. The trial met its primary efficacy endpoint, demonstrating superiority to plain balloon angioplasty.